Kiniksa Pharmaceuticals International (KNSA) Assets (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Assets came in at $896.1 million in Q2 2026, up 35.54% YoY from $661.2 million in Q2 2025, and up 8.58% on a QoQ basis from $825.3 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Assets (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Assets data on file, last reported at $896.1 million in Q2 2026.
- Quarterly Assets rose 35.54% year-over-year to $896.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $896.1 million (up 35.54% YoY) and the FY2025 annual result came in at $763.6 million, up 31.54% from the prior year.
- Assets advanced to $896.1 million in Q2 2026, from $825.3 million in the prior quarter.
- In the past five years, Assets ranged from a high of $896.1 million in Q2 2026 to a low of $210.6 million in Q2 2022.
- A 5-year average of $553.0 million and a median of $534.4 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets retreated 25.77% — and 2023, when it jumped 130.0%.
- Tracing KNSA's Assets over 5 years: stood at $459.7 million in 2022, then gained by 14.5% to $526.3 million in 2023, then advanced by 10.3% to $580.6 million in 2024, then surged by 31.54% to $763.6 million in 2025, then grew by 17.35% to $896.1 million in 2026.
- The last three Assets figures came in at $896.1 million (Q2 2026), $825.3 million (Q1 2026), and $763.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.00 Bn | 43.04 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.10 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.92 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.21 Bn | 19.54 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.55 Bn | 220.03 Mn | 896.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 896.11 Mn |
| Mar 31, 2026 | 825.28 Mn |
| Dec 31, 2025 | 763.63 Mn |
| Sep 30, 2025 | 712.33 Mn |
| Jun 30, 2025 | 661.15 Mn |
| Mar 31, 2025 | 599.33 Mn |
| Dec 31, 2024 | 580.55 Mn |
| Sep 30, 2024 | 555.30 Mn |
| Jun 30, 2024 | 542.43 Mn |
| Mar 31, 2024 | 519.67 Mn |
| Dec 31, 2023 | 526.32 Mn |
| Sep 30, 2023 | 483.06 Mn |
| Jun 30, 2023 | 484.33 Mn |
| Mar 31, 2023 | 442.86 Mn |
| Dec 31, 2022 | 459.67 Mn |
| Sep 30, 2022 | 459.95 Mn |
| Jun 30, 2022 | 210.58 Mn |
| Mar 31, 2022 | 230.97 Mn |
| Dec 31, 2021 | 232.80 Mn |
| Sep 30, 2021 | 252.86 Mn |